Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD
A First-in-Class Ophthalmological Recombinant Fully Human Bi-specific Fusion Protein Targeting VEGF and Complement Proteins SUZHOU, China, April 18, 2019 /PRNewswire/...